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The pandemic of COVID-19, caused by the coronavirus, SARS-CoV-2, has had a global
impact not seen for an infectious disease for over a century. This acute pandemic has
spread from the East and has been overlaid onto a slow pandemic of metabolic diseases
of obesity and diabetes consequent from the increasing adoption of a Western-lifestyle
characterized by excess calorie consumption with limited physical activity. It has become
clear that these conditions predispose individuals to a more severe COVID-19 with
increased morbidity and mortality. There are many features of diabetes and obesity that
may accentuate the clinical response to SARS-CoV-2 infection: including an impaired
immune response, an atherothrombotic state, accumulation of advanced glycation end
products and a chronic inflammatory state. These could prime an exaggerated cytokine
response to viral infection, predisposing to the cytokine storm that triggers progression to
septic shock, acute respiratory distress syndrome, andmulti-organ failure. Infection leads
to an inflammatory response and tissue damage resulting in increased metabolic activity
and an associated increase in the mechanisms by which cells ingest and degrade tissue
debris and foreign materials. It is becoming clear that viruses have acquired an ability to
exploit these mechanisms to invade cells and facilitate their own life-cycle. In obesity and
diabetes these mechanisms are chronically activated due to the deteriorating metabolic
state and this may provide an increased opportunity for a more profound and sustained
viral infection.
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The current global pandemic is the third epidemic of a major severe acute respiratory syndrome
(SARS) caused by a coronavirus this century. The initial SARS epidemic in 2002 affected 29
countries, primarily in the far east, with 8,098 cases and 774 fatalities (1). This was followed 10 years
later by the Middle-East Respiratory Syndrome (MERS) in 2012 that affected 27 countries, mainly
in the middle-east, with 2,494 cases and 858 deaths (1). Seven years later another coronavirus,
SARS-CoV-2, closely resembling SARS-CoV-1, originated in China in late 2019 but has since spread
to 213 countries and as of early August 2020 there have been over 20 million cases worldwide
with three-quarters of a million deaths (www.worldometers.info/coronavirus/). As such this is the
first coronavirus to have a major impact on Western countries. In contrast to many places in
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Asia, Africa, and South America, over the last century most
infectious diseases have become well-controlled in the West.
However, growing epidemics of chronic diseases linked to
lifestyle, such as cardiovascular disease, obesity and diabetes,
that first became apparent in the West, have now spread to
other regions of the world that have adopted a Western lifestyle
and have slowly become global pandemics. The obesity and
diabetes epidemics are also now prevalent in the Middle East
and in the East; a cross-sectional survey of 170,287 participants
in China in 2013 estimated that 47% of the adult population
had either diabetes or prediabetes (2), The SARS-CoV-2 is the
first acute pandemic in which an infectious disease from the East
has collided with the slow pandemic of chronic lifestyle-related
conditions from the West with severe consequences.
In contrast to the previous coronavirus epidemics, SARS-
CoV-2 has spread more widely because its transmission has been
facilitated by being highly contagious, in combination with a
long latency period and large numbers of asymptomatic carriers
(3). The SARS-CoV-2 virus results in a disease, COVID-19,
that in some individuals can progress from a mild respiratory
infection to a generalized inflammatory state, acute respiratory
distress syndrome (ARDS) and ultimately multi-organ failure
(MOF) associated with a high mortality rate (4). There are now
seven coronaviruses that have spread to humans with HCov-
229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 thought to
be responsible for around 30% of cases of the common cold
(5). In around 80% of individuals, infection with SARS-CoV-
2 can similarly result in mild or no discernible symptoms, but
in around 20% of those infected COVID-19 can progress to
severe outcomes with a high risk of mortality. The risk of severe
disease is greatly enhanced by co-morbidities; the most common
co-morbidities conferring the greatest risk are the chronic
conditions associated with a Western-lifestyle; cardiovascular
disease, obesity, and diabetes (6). A Western lifestyle is
characterized by increased consumption of energy-dense foods
and reduced physical activity leading to metabolic dysregulation
with the global incidence of diabetes estimated to be some 463
million people in 2019 (7). The enforced stay-at-home/shield-in-
place orders, that became almost universal, potentially resulted in
reduced physical activity, altered nutritional intake and increased
stress levels; all factors that could aggravate these conditions. In
addition, reduced sun-light exposure and consequently reduced
Vitamin D, reducing its anti-inflammatory actions (8) could
also potentiate insulin-resistance (9). Indeed, using a simulation
model that was created using glycemic data measured during
previous disasters in India, with a similar impact to the current
lockdown, it was predicted that after 45 days of lockdown
glycemic control would deteriorate in patients with diabetes with
a 3.68% increase in HbA1c (10).
OBESITY, DIABETES EFFECTS ON
COVID-19 RISK, AND SEVERITY
That the metabolic disorder of diabetes was associated with
COVID-19 was reported during the original outbreak in China
and as the epidemic spread to Italy and the USA this was
confirmed and similar associations were then also observed
with obesity (11) A meta-analysis of 6 studies from China, that
included 1,527 confirmed cases with SARS-CoV-2 infections,
found a prevalence of diabetes among the patients of 9.7%
compared to a prevalence within the general Chinese population
of 10.9% (12) and an audit of 146 patients hospitalized with
COVID-19 in Padova in Italy observed a prevalence of 8.9%
(95% CI 5.3–14.6) compared to a prevalence of 11.0% in the
same region (13). These preliminary reports would suggest that
subjects with diabetes have no increased susceptibility to being
infected; however, such conclusions are premature as there are
many confounding issues that are yet to be examined including
patients with obesity or diabetes being more likely to stay at
home during such epidemics, being less mobile, have fewer
social contacts and hence may have less exposure to the virus.
Furthermore, the question of whether pre-existing diabetes or
obesity predispose to acquiring an infection with SARS-CoV-
2 is not possible to assess from reports of incident cases that
depend considerably on the existing testing regimes which have
varied greatly as the pandemic has developed and across different
countries. If these conditions increased the severity of symptoms
then there could be ascertainment bias in testing and detection
of cases. Whether these preconditions predisposed to infection
will only be answered when serological studies, monitoring the
presence of viral antibodies in populations, have been completed
with appropriate consideration for all confounding issues.
In contrast to the uncertainty regarding potential effects on
the risk of infection, it is now clear that pre-existing diabetes
and/or obesity have profound effects on the subsequent course
of disease with many consistent reports of strong associations
with morbidity and mortality. In the original outbreak in
Wuhan it was observed that diabetes was associated with a
higher risk of severe pneumonia, release of tissue injury-related
enzymes, excessive uncontrolled inflammatory responses, and a
hypercoagulable state (14). A report from the Center for Disease
Control and Prevention in China, summarizing findings from
72,314 cases, observed that the overall case fatality rate was 2.3%,
but for cases with diabetes the fatality rate was 7.3% (15). A review
of hospital records of 1,099 patients in China found that the
overall prevalence of diabetes was 7.4%; however, in those who
required intensive care or mechanical ventilation or who died the
prevalence was 26.9% compared to a prevalence of 6.1% in those
without these indications of severe disease (16). A similar review
of patient charts in Italy found that of 355 deaths 35.5% had pre-
existing diabetes (6). A review of 5,279 confirmed infections at a
single Medical Center in New York observed that overall 22.6%
had pre-existing diabetes, but in those not requiring hospital
admission only 9.7% had diabetes compared to 34.7% of those
admitted (17). An initial assessment of co-morbidities among
affected cases in the USA by the Center for Disease Control found
that of 7,162 cases with full records overall 10.9% had diabetes
but the prevalence was only 6% of those not requiring hospital
admission compared to 24% of those requiring admission and
32% of those subsequently admitted to Intensive Care Units
(ICU) (18). A study of 1,158 patients admitted to hospital in
Kuwait, of which 104 needed ICU care, found the prevalence
of diabetes to be 23.4% and in a multivariate analysis diabetes
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increased the risk of need for subsequent ICU with an OR 5.49
(CI 3.13, 9.65) (19).
There have also now been several meta-analyses of the many
studies documenting the effects of diabetes and obesity on the
severity and outcomes of COVID-19. A meta-analysis including
data from 31 studies with a total of 6,104 cases found that cases
with pre-existing diabetes had an OR of 2.61 (CI 2.05, 3.33) for
developing severe COVID-19 compared to cases without diabetes
(20). Another meta-analysis of 14 studies including 4,659 cases
from China and USA with a prevalence of diabetes of 23.8%
found that pre-existing diabetes increased the risk of death with
OR 2.0 (CI 1.7, 2.3) (21). A larger meta-analysis including 33
studies with 16,003 cases found a prevalence of diabetes overall of
11.2%, but sub-group analysis revealed a prevalence of 10.5% of
cases in China and 19.3% of cases outside of China (mainly USA):
diabetes increased the risk of severe disease with OR 2.75 (CI
2.09, 3.62) and death with OR 1.90 (CI 1.37, 2.64) (22). A further
meta-analysis of 30 studies with 6,452 cases found that diabetes
increased the risk of severe COVID-19 with OR 2.45 (CI 1.79,
3.35), of ARDS with OR 4.64 (CI 1.68, 11.58) and of death with
OR 2.12 (CI 1.44, 3.11) (23). When all of these outcomes were
combined in an analysis of composite poor outcome, diabetes
increased the risk with OR 2.38 (CI 1.88, 3.03) and a subgroup
analysis revealed the risk was stronger in the younger cases with
median age<55 years-old (RR 3.48) compared to older cases≥55
years-old (RR 1.92) (23).
Associations between obesity and severity of COVID-19 or
mortality have similarly been consistently reported. An audit of
124 patients admitted to ICU in France observed that among
patients with COVID-19, obesity (BMI >30–<35 kg/m2) and
severe obesity (BMI >35 kg/m2) were more prevalent than
in control patients admitted to ICU for other causes: 47.6 vs.
25.2% and 28.2 vs. 10.8%, respectively, and those requiring
invasive mechanical ventilation were also more obese (24). In
a multivariate analysis of hospitalized patients in Kuwait, the
risk of requirement for ICU was increased in the obese OR 2.7
(CI 1.17, 6.20) and those with morbid obesity (BMI >40) OR
3.95 (CI 1.0–15.2) (19). A similar study from New York that
included 1,331 hospitalized COVID-19 patients, of whom 431
were admitted to ICU, found that the association with obesity
was only evident in younger patients <60 years old with a higher
risk of ICU admission for those with obesity (OR 1.8, CI 1.2,
2.7) and severe obesity (OR 3.6, CI 2.5, 5.3) compared to patients
with a BMI <30 (25). An observational study of 20,133 patients
admitted to 208 hospitals across the UK found that obesity
increased the risk of death OR 1.33 (CI 1.19, 1.49) (26).
These observations are consistent with the long-known effects
of obesity and diabetes on the severity and prognosis of
infections. Influenza is often more severe and more often results
in pneumonia in subjects with diabetes (27, 28). Following the
influenza pandemic due to the H1N1 virus in 2009 obesity
was recognized as a risk factor for hospitalization, the need for
mechanical ventilation and death (29, 30). Plasma glucose and
pre-existing diabetes were reported to be independent risk factors
for morbidity and mortality in the original SARS epidemic in
2002 (31) and diabetes was strongly associated with mortality in
the MERS epidemic in 2012 (32).
OBESITY, DIABETES AFFECT THE HOST
RESPONSE TO SARS-COV-2
Themetabolic derangements associated with obesity and diabetes
have multiple effects on how the body responds to viral infections
that could impact on the course of the disease. The most
fundamental effect, that underpins the generalized increased
predisposition to all infections, is the compromised immune
system that is secondary to the metabolic derangements in
obesity and diabetes. Interestingly, just a few years ago, as the
health problems associated with a Western lifestyle spread to
tropical regions, it was prophesized that this would pose a
large threat for subjects with diabetes who contracted infectious
diseases (33). With SARS-CoV-2 this threat is no longer confined
geographically but has now become a global reality. Many
aspects of the innate and adaptive immune systems are impaired
in diabetes and obesity including inappropriate T-cell action,
impaired natural killer cell activity, phagocytic cell dysfunction,
inhibition of neutrophil chemotaxis, and defects in complement
action (34–37). The compromised immune system in subjects
with diabetes results in impaired responses to many of the stimuli
activated during infections (38). Another potential consequence
of the impaired immune cell function is that viral clearance
could be reduced. A recent report measuring the interval between
hospital admission and two negative tests for SARS-CoV-2
RNA, at least a day apart, found some evidence that there
was delayed viral clearance in patients with diabetes (39). In
addition, they found evidence that the use of glucocorticoids
could also delay viral clearance (39) which is significant as
glucocorticoids are frequently used for patients with ARDS
(40). Indeed, glucocorticoid use is known to impair glycaemic
control (41) and has been reported to reduce angiotensin-(1-7)-
Mas receptor expression (42). However, although glucocorticoid
use has been advised against in patients with COVID-19 (43)
this advice has been questioned with a suggestion that low-to-
moderate dose glucocorticoid could still be beneficial in treating
critically ill patients with COVID-19 (44). Critical illness is
associated with corticosteroid insufficiency (45) and there are
cogent arguments for the use of glucocorticoids in critically ill
patients (46) especially for treating ARDS (47). Consistent with
this glucocorticoid treatment was found to reduce mortality in
critically ill patients with SARS (48). A recent report confirmed
similar findings in patients with COVID-19: in 2,014 patients
randomized to receive dexamethasone, 28-day mortality was
unaffected in subjects receiving no respiratory support but was
reduced in critically ill patients receiving oxygen without invasive
mechanical ventilation and was even more reduced in those
receiving invasive mechanical ventilation (mortality rate ratio,
0.64; 95% CI, 0.51–0.81) (49). The compromised immune system
in subjects with diabetes also increases susceptibility to potential
secondary bacterial infection in the lungs (50).
Both obesity and type 2 diabetes are associated with
chronic low-grade inflammation. Excess calorie intake results
in a stimulation of pancreatic β-cell insulin secretion with
the increase in oxygen consumption resulting in cell stress
and mild inflammation. The insulin promotes glucose uptake
and enlargement of adipocytes that in turn causes activation
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and recruitment of resident macrophages in adipose tissue.
The adipocytes and macrophages then release more of a
variety of proinflammatory cytokines and chemokines (including
interleukin-1 (IL-1), IL-6, IL-8, monocyte chemoattractant
protein-1 (MCP-1), C-reactive protein (CRP)) and less anti-
inflammatory cytokines and adipokines (including IL-4, IL-10,
IL-13, and adiponectin) (51, 52). These factors can then aggravate
insulin-resistance leading to increased pancreatic insulin release
and establish a vicious cycle. In subjects with obesity and
diabetes the chronic low-grade inflammatory state could then
aggravate the inflammatory response to SARS-CoV-2 infection
and precipitate the hypersensitivity state and cytokine storm that
can lead to pneumonia, ARDS and ultimately MOF observed
in severe COVID-19 cases (16, 53, 54). Consistent with this,
higher levels of IL-6, CRP and fibrinogen were observed in
COVID-19 patients with diabetes compared to those without
(14). The cytokine storm is part of an evolutionary conserved
stress response preparing the body for a severe insult (55) with
activation of the hypothalamic-pituitary-adrenal (HPA) axis (to
produce cortisol), the sympathetic nervous system (to generate
catecholamines), a tissue defense response and an acute-phase
reaction, to generate pro-coagulant factors, in preparation for
tissue damage.
Insulin-resistance, obesity, and diabetes promote an
atherothrombotic state due to a disturbance in the balance
of factors regulating coagulation and fibrinolysis with an increase
in many clotting factors (such as tissue factor and fibrinogen)
and adhesion molecules (such as P-selectin), a reduction in
anticoagulant proteins (such as antithrombin) and a reduction
in fibrinolysis due to an increase in plasminogen activator
inhibitor type-1 (PAI-1) (56, 57). These factors could increase
the likelihood of the development of endothelial dysfunction
and platelet aggregation promoting the formation of occlusive
thrombus in the heart and lungs in COVID-19 patients with
diabetes. In patients with COVID-19 however there are increased
levels of fibrinogen, CRP, and D-dimer (14, 58), with elevated
D-dimer levels being a risk factor for mortality (53) these
findings indicate that there appears to be an increase not
only in coagulation but also in fibrinolysis. An imbalance or an
impairment of coordination between coagulation and fibrinolysis
appears to be responsible for much of the pathology observed
in COVID-19 (59). The dysregulation of the system in subjects
with obesity and diabetes could then exacerbate the effects of
COVID-19 (60). Indeed, lung, heart, and brain damage appear
to be common pathological findings in COVID-19 associated
with fibrotic clots and disseminated intravascular coagulation
(61, 62).
Severe obesity is associated with restrictive lung function
with decreased expiratory reserve volume, functional capacity,
and respiratory system compliance. These factors can complicate
the clinical management of obese COVID-19 patients and in
subjects with excess abdominal adipose tissue the diaphragmatic
excursions are compromised and this can make assisted
ventilation more problematic (63).
Diabetes and hyperglycaemia are accompanied by an
accumulation of advanced glycation end-products (AGEs) that
interact with a specific cell surface protein, the receptor for
AGEs (RAGE). This has subsequently been found to be a pattern
recognition receptor (PRR) that also recognizes pathogen-
associated molecular patterns (PAMPs) from microorganisms,
as well as danger-associated molecular patterns (DAMPs)
released by stressed or damaged cells and play a key role in
the inflammatory response (64). Although RAGE is normally
expressed at low levels in most tissues and increased during
inflammation, it is expressed at high levels in Type I and Type II
alveolar epithelial cells (AT1, AT2) in the lung and appears to be
a critical mediator of the pulmonary inflammatory response (65).
In addition, it has been shown that activation of the Angiotensin
II receptor 1 (AT1R) by Angiotensin II (AngII) can transactivate
RAGE and that this mediates the subsequent inflammatory
response (66). It has been suggested that RAGE may aggravate
the inflammation and coagulation observed in COVID-19 (67)
and contributes to the lung pathology (68). Infection with
SARS-CoV-2 perturbs the renin–angiotensin system favoring
AT1R activation (see below) and hence potentially transactivating
RAGE, which is also activated by accumulated AGEs in patients
with diabetes, aggravating the inflammatory and fibrotic response
and promoting lung damage.
In addition to the general effect of inflammatory cytokines
aggravating insulin-resistance, it had previously been reported
that the SARS-CoV-1 receptor, which is the same receptor used
by SARS-CoV-2, was abundantly expressed in the pancreas and
that a proportion of patients with SARS developed transient
diabetes during the course of the disease (69). This suggests
that infection with SARS-CoV-2 could lead to a deterioration in
metabolic control via a number of mechanisms and themetabolic
derangements could, in turn, promote a more severe disease; this
could be a particular problem in patients with obesity and those
with type 2 diabetes who have residual pancreatic function in
whom metabolic perturbations were already present.
OBESITY, DIABETES, AND THE VIRAL
PATHWAY
In addition to the many established mechanisms whereby
metabolic disorders could promote a more severe clinical
response to SARS-CoV-2; the emerging evidence, uncovering
how the virus infects cells, has indicated many further links to
endocrine and metabolic controls. This has raised the prospect
that obesity and diabetes could promote the course of the
viral infection within the body. In order to enter and infect
host cells the virus appears to have hijacked mechanisms that
have evolved to ingest and degrade foreign material; with
SARS-CoV viral entry occurring mainly by endocytosis via the
endosomal/lysosomal route (70)(Figure 1).
Angiotensin Converting Enzyme 2 (ACE2)
The initial attachment of SARS-CoV-2 virus to cells has been
reported to be mediated by ACE2, a transmembrane protein
known to be important in the renin-angiotensin system (RAS)
(71, 72). There are two immediate implications: the pattern of
expression of ACE2 may determine the tissues in the body that
are most affected by infection and secondly the virus may perturb
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FIGURE 1 | SARS-CoV-2 viral entry to host cell pathway. The SARS-CoV-2 virus attaches to host cell surfaces via specific receptors, ACE2 and CD147, via spike
protein (S1) projecting from the viral envelope. The spike protein first has to be “primed” by proteolytic cleavage by TMPRRS2 which can also cleave ACE2 resulting in
shedding of the ectodomain. In contrast to TMPRSS2, which facilitates virus binding, ACE2 can also be cleaved by ADAM17, which prevents viral binding and results
in shedding of the ACE2 ectodomain that can still bind to SARS-CoV-2 and act as a decoy receptor reducing viral infection. The entry of the virus is facilitated by the
protein chaperone, GRP78 that also binds to the spike protein. Metabolic stress in the host cell results in upregulation of GRP78 and its translocation to the cell
surface. On the cell surface ACE2, CD147, GRP78, TMPRSS2, and ADAM17 all cluster within organized cholesterol-rich domains called lipid rafts and together can
enable viral entry via endocytosis. Viral replication within the cell can also be facilitated by GRP78.
the normal function of RAS which could impact the course of
the disease. Two forms of ACE2 are found in the body, the full-
length transmembrane form and a soluble form generated by
proteolytic shedding of the extracellular domain of ACE2. The
normal enzyme function of ACE2 is to degrade AngII to Ang-
(1-7) and to a lesser extent AngI to Ang-(1-9); this in effect then
opposes the action of ACE which converts Ang I to Ang II (73).
The RAS plays an important role in regulating vascular function,
blood pressure, and fluid and electrolyte balance. It comprises
a dynamic counter-regulatory system with Ang II, the product
of ACE, activating the AT1R to promote vasoconstriction, salt
and water retention, fibrosis, and inflammation whereas the
product of ACE2, Ang-(1-7) activates the G protein-coupled
receptorMas-receptor (MasR) to stimulate vasodilation and anti-
inflammatory effects. The expression of ACE2 has been described
in a number of tissues including the heart, kidneys, pancreas,
and both type I and type II alveolar epithelial cells (ATI, ATII)
in the lungs (74, 75). In addition to its well-known role in the
cardiovascular system, the RAS also plays a critical role in lung
function and disturbances to the ACE/ACE2 balance can lead to
pulmonary disease. Knock-out of ACE2 in mice results in severe
ARDS (76). In addition, ACE2 was shown to play an important
role in lung injury in mice infected with H5N1 (77) and also
infected with SARS-CoV-1 (78).
It has also become increasingly clear that ACE2 may play
an important role in metabolic regulation. Knock-out of the
ACE2 gene in mice resulted in a deficiency of pancreatic
insulin secretion that was partially countered by increased
glucose utilization in muscle (79, 80). Knock-down of ACE2
also compromises pancreatic function in obese mice (81). In
an experimental model in which a high-calorie diet induces
insulin resistance in mice, knock-down of ACE2 exaggerates
the insulin resistance by reducing glucose uptake into tissues
(82). Furthermore, overexpression of ACE2 improved glycaemic
control in a model of type II diabetes in mice (83). In addition
to SARS-CoV-2 directly infecting the pancreas via ACE2 and
causing transient diabetes (69) the interaction of the virus with
ACE2 could therefore have other effects to perturb the RAS and
further compromise metabolic control.
The levels of ACE2 have been reported to be decreased in some
experimental models of diabetes (84) and the loss of the counter-
regulatory protective effects of the RAS has been speculated
to potentiate lung damage. However, other reports indicate
increased levels of ACE2 in the heart, liver, and lungs of mice with
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diabetes (85) and it has been suggested that this could make these
tissues more vulnerable to SARS-CoV-2 infection and contribute
to an increased risk of MOF in patients with diabetes. Evidence
from humans indicate that levels of ACE2 in urine are increased
in patients with type I diabetes (86) and type II diabetes (87) and
positively related to blood glucose and HbA1c levels (88). It is not
yet clear however, whether increased ACE2 in the urine is due to
increased shedding of ACE2 in the kidney or whether it reflects
increased circulating or systemic tissue levels. However, increased
serum levels of ACE2 have been reported in subjects with diabetes
and obesity (89). Expression of ACE2 in sputum cells has also
been reported to be increased in subjects with diabetes and
to be decreased in subjects using inhaled corticosteroids (90).
Furthermore, a Mendelian Randomization study indicated that
diabetes was causally related to increased ACE2 expression in
lung tissue (91). An increase in ACE2 expressionwas also recently
reported in the kidney of patients with diabetic kidney disease
(92) and in the liver of patients with diabetes and also subjects
with non-alcoholic fatty liver, which is prevalent in subjects with
prediabetes (93). The weight of evidence therefore suggests that
ACE2 levels are probably increased in various tissues in humans
with diabetes and as evidence from cell biology suggests this may
increase viral entry, this implies that infection with SARS-CoV-2
may be increased in tissues such as the lung, liver and kidney.
Following binding of SARS-CoV to ACE2, the complex is
endocytosed and proteolyzed resulting in reduced tissue levels
of ACE2 (94–96). Consistent with a down-regulation of ACE2,
increased levels of AngII have been observed in patients with
COVID-19 and these correlated with viral load (97). The
increased levels of Ang II, together with potentially reduced
levels of Ang-(1-7), would shift the balance of RAS actions
to pro-inflammatory, rather than anti-inflammatory, resulting
in increased lung damage as has been shown in experimental
models of SARS (76, 78). However, it has recently been reported
that expression of ACE2 can be upregulated by inflammatory
cytokines (98) and this has also been reported to occur in
airway epithelium (99). The chronic inflammatory state found
in diabetes and obesity could facilitate viral infection via such a
mechanism. In addition, insulin decreases expression of ACE2
(85, 100) suggesting that metabolic regulators could play an
important role in affecting viral entry and/or in altering the
inflammatory response by shifting the balance in the RAS. It has
also been reported that the virus itself could upregulate ACE2
expression suggesting a positive feed-forward loop to enhance
infection (101).
THE TYPE II TRANSMEMBRANE SERINE
PROTEASE (TMPRSS2)
The virus interacts with ACE2 via a specific spike protein (S-
protein) projecting from its envelope. The S-proteins of SARS-
CoV viruses are typical class I viral fusion proteins that first need
to be cleaved by proteases to activate their fusion ability that
enables the virus to invade the host cell (70). The S protein is
cleaved into two subunits (S1 and S2); the S1 subunit is then
further divided into SA and SB domains, with the SB domain
predicted to bind to human ACE2. This is often referred to as
S-protein priming. The S2 subunit is responsible for fusion of
the virus–ACE2 complex with the cell membrane. The enzyme
responsible for S-protein priming and SARS-CoV-2 entry has
been identified as TMPRSS2 and a clinically approved TMPRSS2
inhibitor, Camostat, markedly reduced viral entry into cultured
lung cells (102). Similar results were reported previously for
SARS-CoV-1 cell entry (103).
Expression of TMPRSS2 has been described in epithelial
cells across a variety of tissues including prostate, colon, small
intestine, pancreas, kidney, liver, and lung (104). It has been
most studied in the prostate where it is strongly upregulated
by androgens via an androgen-responsive promoter enhancer
in the TMPRSS2 gene (105). Interestingly, it has also been
reported to be upregulated on lung cells by both androgens
and glucocorticoids (106). The strong androgen dependence
of TMPRSS2 could contribute to the increased risk for men
with COVID-19 (107). In addition to cleaving the S-protein,
TMPRSS2 also cleaves ACE2 resulting in shedding of its
ectodomain creating a soluble form of ACE2. This then competes
with the normal shedding of ACE2 due to cleavage by the
cell surface protease a disintegrin and metallopeptidase domain
17 (ADAM17) also known as tumor necrosis factor-converting
enzyme (TACE) (108). Cleavage and shedding of ACE2 by
ADAM17 prevents the action of TMPRSS2 to facilitate viral entry
and in addition the soluble shed ACE2 can still bind to the viral
S-protein and hence can compete with cell surface binding and
protect tissues from infection acting as a decoy receptor (103).
Although, as described above, a loss of the counter-regulatory
protective effects of the RAS may enhance the damage in already
infected lungs.
Whether TMPRSS2 has a role in metabolic regulation has yet
to be investigated. The TMPRSS2 inhibitor, Camostat, has been
reported to correct some of the metabolic abnormalities present
in rats with diabetes and obesity (109), however, it is not clear that
these effects were specific to inhibition of TMPRSS2.
LIPID RAFTS
Viral entry depends on an interaction between the virus S-
protein and both ACE2 and TMPRSS2 on host cell surfaces
and this occurs within organized domains called lipid rafts that
are rich in cholesterol and sphingolipids; agents that disrupt
lipid rafts prevent SARS-CoV-2 viral entry (110, 111). Lipid
rafts were previously shown to play a role in SARS-CoV-1
infection (112), specifically that the interaction of SARS-CoV-1 S-
protein with ACE2 occurred within lipid rafts (113). Indeed, lipid
rafts have previously been implicated as important cell surface
domains for the entry of other viruses (114, 115). An increase in
cholesterol increases the availability of SARS-CoV-2 viral entry
points (111). As cholesterol levels increase with aging and with
metabolic disorders this could contribute to their associations
with the severity of COVID-19. In addition, 7-ketocholesterol
(7-KC) and 25-hydroxycholesterol (25-HC; a major circulating
metabolite of cholesterol), can replace cholesterol in lipid rafts,
disrupting their organization and these oxysteroids have been
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reported to have anti-viral activity (116–119) including against
a porcine coronavirus (120). Inflammatory cytokines stimulate
the formation of 25-HC, which in turn, promotes adipose tissue
inflammation that is found in diabetes and obesity (121). The
targeting of cholesterol and lipid metabolism and distribution
has been proposed as a novel strategy for treating viral infections
(122). The need for clustering of ACE2 and TMPRSS2 within
organized domains in lipid rafts for viral entry could help
explain some of the seemingly discrepant reports that increased
ACE2 could facilitate infection, as described above, or actually
protect against infection (123). With ACE2 present as a soluble,
shed form that could act as a decoy-receptor and on cell
surfaces in raft and non-raft domains, the total abundance
may be less important than the localization and distribution
of ACE2.
CD147
In addition to the virus gaining entry to host cells via an
interaction of the viral S-protein with ACE2, viral entry has
also been reported to occur via an interaction between the
S-protein and CD147, with viral entry blocked by an antibody
to CD147 (124). Again, this route had previously been reported
for SARS-CoV-1 (125) and for other viruses including hepatitis
B, human cytomegalovirus, Kaposi’s sarcoma–associated
herpesvirus, measles and HIV-1 (126–128). In turn, viral
infection of host cells leads to upregulation of CD147 (129).
CD147, which is also known as Basigin or extracellular matrix
metalloproteinase inducer (EMMPRIN), is a transmembrane
glycoprotein that belongs to the immunoglobulin superfamily
(126). CD147 is expressed in a number of cells in the
lungs and its expression is increased in patients with chronic
obstructive pulmonary disease (COPD) (130) and at sites of
lung fibrosis (131). The expression of CD147 on the cell
surface is upregulated by high glucose levels and by AGEs,
via activation of RAGE, and has been suggested to play a
role in diabetic complications (132). On cell surfaces CD147
is found within lipid rafts associated with caveolin-1 (133).
In addition, HMG-CoA reductase inhibitors, statins, inhibit
the cholesterol biosynthesis pathway and disrupt lipid raft
composition resulting in a reduction of CD147 translocation to
the cell surface (134). In addition to playing a role in viral entry,
CD147 has a role in the immune response by modulating T-
cell activation (135). One of the other prime functions of CD147
appears to be as a chaperone for monocarboxylate transporters
(MCTs) that facilitate the transport of monocarboxylates such
as lactate across the plasma membrane (136). In addition,
CD147 is colocalized and associates with the glucose transporter,
GLUT1, on cell surfaces (137) and an increase in CD147
is accompanied by an increase in GLUT1 and a switch to
more glycolytic metabolism (138). Therefore, CD147 appears
to be an important determinant of cell metabolism and in
addition to facilitating SARS-CoV-2 entry and modulating the




A further important component in viral entry appears to be
GRP78. Molecular modeling predicts that the SARS-CoV-2 S-
protein should bind to GRP78 with high affinity (139). This
would be consistent with a previous report that GRP78 bound to
the S-protein of other coronavirus and was permissive for their
entry to host cells, including MERS-CoV and HKU9 (140). The
most well-established role of GRP78 is as a protein chaperone
that ensures the correct folding and assembly of proteins in the
endoplasmic reticulum (ER) and in the event of accumulation
of misfolded proteins aids their degradation or initiates the
unfolded protein response (UPR) or the ER stress response
(141, 142). The chaperone role of GRP78 acts not only in the ER
but also to chaperone proteins entering the cell via endocytosis
(143). As viral proteins are foreign to host cells, viruses that
acquired an ability to engage with host cell chaperones and
disrupt the process designed to degrade unrecognized proteins
would have gained a clear advantage. As such GRP78 binding
appears to be have been commonly acquired by many viruses to
not only ensure safe entry to host cells but also to facilitate viral
replication. When a cell starts to make new viral proteins, it is
an advantage for the virus if these are not immediately degraded.
Infection with Coxsackievirus A9 (CAV-9) causes clustering of
GRP78 with integrin receptors within lipid rafts on host cell
surfaces which together then facilitate viral entry (144). The
endocytosis of Zika virus is also facilitated by cell surface GRP78
(145). Similarly, GRP78 acts as a receptor for Dengue virus
and antibodies to GRP78 could inhibit infection (146). Denge
virus induces increased expression of GRP78 in host cells which
then acts as a chaperone to facilitate viral protein production
and viral replication (147). Similarly, Japanese Encephalitis Virus
not only employs GRP78 as a receptor for host cell entry but
also in facilitating viral replication (148). Although binding to
GRP78 appeared not to be required for the entry of Ebola virus
into host cells, it did play an essential role in viral protein
transcription (149).
While GRP78 belongs to the heat shock protein 70 (HSP70)
family, rather than being induced by heat shock it is induced
by metabolic stress and was named due to observations of its
induction by glycaemic stress (142, 150). The significance of
the metabolic regulation of GRP78 is still far from being fully
understood. However, it is clear that metabolic disturbances can
have profound effects on the expression and functions of GRP78.
Cell surface GRP78 can be shed and circulating GRP78 levels
were found to be increased in subjects with diabetes and obesity
and to correlate with CRP levels, suggesting that the chronic
inflammation could be a contributing factor to the observed
increase in addition to the metabolic stress (151). Indeed, as
well as induction by metabolic stress, inflammatory cytokines
also appear to stimulate the translocation of GRP78 to cell
surfaces (152). Accumulation of AGEs can also induce GRP78
via activation of RAGE (153, 154). In a cell model of diabetic
nephropathy high glucose was shown to upregulate cell surface
GRP78 where it associated with integrin receptors and enhanced
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a fibrotic response (155). Androgens have also been reported
to upregulate GRP78 (156, 157) and this could be a further
contributing factor to the increased risk of COVID-19 in males.
Other relevant functions of cell surface GRP78 are its ability to
bind and stabilize ADAM17 (158) and also bind to tissue factor
and regulate the initiation of coagulation (159).
The chaperone role of GRP78 acts not only in the ER but also
to chaperone proteins entering the cell via endocytosis (143). It
seems that viruses have commonly acquired an ability to bind to
GRP78 and hijack its chaperone function to both facilitate entry
to host cells and to enable the production and assembly of viral
proteins. The role of GRP78 in SARS-CoV-2 infections has yet
to be defined although in a clinical study serum levels of GRP78
were found to be elevated in patients admitted with COVID-19
compared to patients with pneumonia or healthy controls (160).
The available evidence indicates that GRP78 is increased and is
translocated to cell surfaces in patients with metabolic disorders
and this could play an important role in viral entry to host cells
and in viral replication, as well as contributing to the fibrotic and
coagulation responses.
CLINICAL IMPLICATIONS
There are a number of implications from these observations.
Reducing excess weight gain and improving metabolic health, in
addition to all of the obvious well-known health benefits, may
help prevent against a severe COVID-19 response to infection.
Special protection/shielding should be provided to those with
pre-existing obesity and diabetes. However, in contrast to the
implication that the androgen dependence of COVID-17 severity
may offer a strategy for using counter-measures to protect
against COVID-19 (161), the metabolic effect needs more careful
consideration. The management of metabolic control in critically
ill patients is much more challenging than in those not acutely
ill and many of the normal drugs used in diabetes are counter-
indicated, with insulin being the most appropriate therapy (162).
In addition, there are good reasons why glucocorticoids, which
may seem counter-indicated, may actually be very beneficial
in critically ill patients (46). In addition, the intense focus on
SARS-CoV-2 has led to many advances in our understanding of
the viral pathway that could provide new targets for developing
more effective therapies against this and other viruses. The use
of statins may have several benefits: the disruption of lipid raft
composition (134) could reduce the various pathways of viral
entry (163). In addition, statins have general anti-coagulant and
anti-inflammatory effects (163); the latter could be particularly
beneficial in combination with glucocorticoids in critically ill
patients (46).
SUMMARY
The consequences of adopting a lifestyle, consuming excess
calories with limited physical activity, are the metabolic
derangements culminating in diabetes and obesity that are now
at pandemic levels throughout the West. It has become clear
that these conditions predispose individuals to severe COVID-
19 that is caused by a virus spreading from the East, that
in the majority of cases causes mild influenza-like symptoms.
There are many consequences of diabetes and obesity that may
accentuate the clinical response to SARS-CoV-2 infection. These
include an impaired immune response, an atherothrombotic
state, accumulation of AGEs activating RAGE and especially the
pre-existing chronic inflammatory state. The later could prime
an exaggerated cytokine response to viral infection, predisposing
to the cytokine storm that triggers progression to septic shock,
ARDS, and MOF.
In addition, to all of these factors that may contribute to
these metabolic conditions exacerbating the clinical course of
COVID-19, there are more fundamental mechanisms that may
contribute to facilitating the viral infection. Infection leads to
an inflammatory response and tissue damage and this results in
increasedmetabolic activity. This is associated with an increase in
the mechanisms by which cells ingest and degrade tissue debris
and foreign materials. It appears that viruses have acquired the
ability to exploit these mechanisms to invade cells and facilitate
their own life-cycle. In obesity and diabetes thesemechanisms are
chronically activated due to the perturbed metabolism and this
may provide an increased opportunity for a more profound and
sustained viral infection.
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